Tagged with IRA

Saudi Arabia Fadi Ghanayem, Managing Director for Saudi Arabia and Caucasus, Central Asia, Iran and Mongolia (CCAIM) at French diagnostics firm BioMérieux discusses the remarkable growth he has witnessed in Saudi Arabia thanks to the government’s push to improve healthcare and prevention in recent years.  In addition, he outlines the opportunities that…

Spain A roundup of the biggest stories emerging from Spain’s pharma industry: Grifols pushes to improve governance after accusations of overstated earnings; Rovi and Insud join forces to create Spain’s first semi-public pharmaceutical company; Almirall and Eloxx Pharmaceuticals sign a licensing agreement for a rare dermatological disease asset, and Esteve acquires…

India Environmental, Social, and Governance (ESG) concerns have grown in global importance in the last few years due to several factors, including increased awareness of and demand for sustainable investing, the need for companies to maintain what McKinsey calls their ‘social license’, and the potential financial benefits of strong ESG performance.…

USA At the American trade association’s latest CEO & Investor Conference, the board chair of the Biotechnology Innovation Organization (BIO) Ted W. Love discussed US policies and speculated about the impact of the upcoming American election on the industry while affirming that biotech continues to thrive in spite of recent challenges.…

USA The Pharmaceutical Research and Manufacturers of America (PhRMA) has had a board reshake, naming Gilead Sciences Chairman and CEO Daniel O’Day as its new chair. The reorganisation comes after the industry group’s failed efforts to block the Inflation Reduction Act (IRA) and the departure of several high-profile members.   Gilead…

USA As part of our Transformative 2023: Regional Pharma Trends report, PharmaBoardroom’s Louis Haynes takes a look at a watershed year for drug pricing in the planet’s most lucrative pharma market.   Drug development is inherently a risky business, but this will compound that risk further… to the point where now,…

USA As the US Inflation Reduction Act (IRA) starts to become a reality, and both big pharma and biotech companies brace themselves for its more widespread impact, BIO names Washington fixture, rare disease advocate and entrepreneur John Crowley as its new CEO.   After waiting for a new leader for over…

India Peter DeYoung shares the significance of Indian giant Piramal Pharma’s recent demerger from its parent company and its current strategic focus on organic growth, brownfield expansions, and “complex hospital generics.” DeYoung also touches on what brought him from the world of consulting and private equity to a family-owned Indian pharma…

USA Nominated by President Joe Biden, the National Institutes of Health’s (NIH) new director Monica M. Bertagnolli took the reins of the world’s largest public funder of biomedical research earlier this month. With a clear focus on improving access and clinical trial diversity, Bertagnolli’s priorities for the role appear to align…

Spain A roundup of the latest news from Spanish pharma, including Almirall’s licensing deal with EpimAb Biotherapeutics; the opening of Insud Pharma’s oligonucleotides centre in India, and Esteve Química’s new FDA-cleared manufacturing site.   Almirall licenses bispecific platform in $210m EpimAb deal (BioProcess International) EpimAb Biotherapeutics has out-licensed the rights for…

UAE Globally, while there is broad stakeholder alignment on topics like clinical trials and innovation, there is real divergence in approaches to pharmacoeconomics and health technology assessment (HTA). This is perhaps in part due to the differences between systems like those in Europe where these functions are state mandates and those,…

USA The subject of intense industry criticism from the likes of lobby groups, Big Pharma, and biotech alike, the Inflation Reduction Act (IRA) subjects certain drugs to price negotiations directly with industry sponsors in the US for the first time. Ten initial drugs – which accounted for over USD 45 billion…